Medicine and Dentistry
Adalimumab
9%
Adverse Event
7%
Biological Product
15%
Biological Therapy
13%
Biosimilar
5%
Clinician
5%
Cohort Analysis
14%
COVID-19
5%
Cyclosporine
6%
Diseases
14%
Elastic Fiber
5%
Etanercept
10%
Fibrillin
7%
Infliximab
5%
Malignant Neoplasm
5%
Methotrexate
5%
Photoaging
6%
Placebo
9%
Prevalence
7%
Psoriasis
100%
Psoriasis Area and Severity Index
9%
Psoriasis Vulgaris
15%
Systemic Therapy
9%
Ultraviolet Radiation
5%
Ustekinumab
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
15%
Adverse Event
7%
Biological Product
17%
Ciclosporin
6%
Cohort Study
13%
Disease
7%
Etanercept
13%
Immunomodulating Agent
6%
Infection
5%
Infliximab
5%
Ixekizumab
5%
Methotrexate
9%
Photoaging
5%
Placebo
12%
Psoriasis
85%
Psoriasis Vulgaris
17%
Secukinumab
5%
Ustekinumab
16%
Immunology and Microbiology
Adalimumab
12%
Biological Product
13%
Cell Migration
5%
Comorbidity
5%
Cytokine
5%
Etanercept
9%
Immunomodulating Drugs
5%
Inflammatory Arthritis
5%
Infliximab
7%
Langerhans Cell
8%
Psoriatic Arthritis
10%
Tumor Necrosis Factor
6%
Ustekinumab
8%